BUND FINANCE › Stocks › ZTS
Zoetis Inc. (ZTS)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 3:59 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +11.60% above its 50-day average.
- It is -6.07% below its 200-day average (long-term downtrend).
- It sits at 26% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$7.8B | US$8.1B | US$8.5B | US$9.3B | US$9.5B |
| Net income | US$2.0B | US$2.1B | US$2.3B | US$2.5B | US$2.7B |
| EPS (diluted) | 4.27 | 4.49 | 5.07 | 5.47 | 6.02 |
| Gross margin | 68.3% | 67.8% | 68.3% | 69.1% | 70.5% |
| Operating margin | 36.1% | 36.2% | 35.9% | 36.7% | 38.0% |
| Net margin | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% |
| Free cash flow | US$1.7B | US$1.3B | US$1.6B | US$2.3B | US$2.3B |
| Total debt | US$6.7B | US$8.1B | US$6.8B | US$6.7B | US$9.3B |
| Cash | US$3.5B | US$3.6B | US$2.0B | US$2.0B | US$2.3B |
Compound annual growth: revenue 5.0% · net income 7.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 14.6x | 35.8x | 27.1x |
| EV / EBITDA | 11.1x | 24.2x | 16.5x |
| Operating margin | 36.3% | — | 3.6% |
| Net margin | 26.2% | — | -0.0% |
| Debt / equity | 3.57 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or proto…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice